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Abstract
Background: Ab deposits represent a neuropathological hallmark of Alzheimer’s disease (AD). Both soluble and
insoluble Ab species are considered to be responsible for initiating the pathological cascade that eventually leads
to AD. Therefore, the identification of therapeutic approaches that can lower Ab production or accumulation
remains a priority. NFB has been shown to regulate BACE-1 expression level, the rate limiting enzyme responsible
for the production of Ab. We therefore explored whether the known NFB inhibitor celastrol could represent a
suitable compound for decreasing Ab production and accumulation in vivo.
Methods: The effect of celastrol on amyloid precursor protein (APP) processing, Ab production and NFB
activation was investigated by western blotting and ELISAs using a cell line overexpressing APP. The impact of
celastrol on brain Ab accumulation was tested in a transgenic mouse model of AD overexpressing the human
APP695sw mutation and the presenilin-1 mutation M146L (Tg PS1/APPsw) by immunostaining and ELISAs. An
acute treatment with celastrol was investigated by administering celastrol intraperitoneally at a dosage of 1 mg/Kg
in 35 week-old Tg PS1/APPsw for 4 consecutive days. In addition, a chronic treatment (32 days) with celastrol was
tested using a matrix-driven delivery pellet system implanted subcutaneously in 5 month-old Tg PS1/APPsw to
ensure a continuous daily release of 2.5 mg/Kg of celastrol.
Results: In vitro, celastrol dose dependently prevented NFB activation and inhibited BACE-1 expression. Celastrol
potently inhibited Ab1-40 and Ab1-42 production by reducing the b-cleavage of APP, leading to decreased levels of
APP-CTFb and APPsb. In vivo, celastrol appeared to reduce the levels of both soluble and insoluble Ab1-38, Ab1-40
and Ab1-42. In addition, a reduction in Ab plaque burden and microglial activation was observed in the brains of Tg
PS1/APPsw following a chronic administration of celastrol.
Conclusions: Overall our data suggest that celastrol is a potent Ab lowering compound that acts as an indirect
BACE-1 inhibitor possibly by regulating BACE-1 expression level via an NFB dependent mechanism. Additional
work is required to determine whether chronic administration of celastrol can be safely achieved with cognitive
benefits in a transgenic mouse model of AD.
Background
Alzheimer’s disease (AD) is an ever-increasing health
concern among the aging population and is the most
common form of dementia affecting more than 25 mil-
lion individuals worldwide. While the cause of the dis-
ease is uncertain, there are two major neuropathological
hallmarks present in the brains of AD patients: the
extracellular senile plaques and the intracellular neurofi-
brillary tangles. Neurofibrillary tangles contain
hyperphosphorylated microtubule-associated protein tau,
while senile plaques contain a core of b-amyloid (Ab)
peptide. Current treatments for AD include cholinester-
ase inhibitors and glutamate antagonists. Although use-
ful, these symptomatic treatments do not stop the
disease process or prevent neuronal degeneration. There
is an on-going need for the development of new treat-
ments for AD. Although the central role of Ab remains
to be proven in clinical trials, data accumulated during
the past two decades place Ab peptides and in particular
soluble forms of the peptide as being the main molecule
initiating the pathological cascade that eventually leads
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to AD [1]. Consequently, significant resources have been
allocated to identify and develop treatment strategies
that alter the metabolism of Ab. To this end, the discov-
ery of new pharmaceutical entities that have Ab-lower-
ing ability remains a priority.
Ab peptides are derived from the sequential proteolysis
of the b-amyloid precursor protein (APP) by b- and g-
secretases. The major b-secretase is an aspartyl protease
termed BACE-1 (b-site APP cleaving enzyme) [2-4].
BACE-1 cleaves APP within the extracellular domain of
APP, resulting in the secretion of the large ectodomain
(APPsb) and generating a membrane-tethered C-terminal
fragment CTFb or C99 which serves as a substrate for
g-secretase [5]. The multimeric g-secretase complex
cleaves at multiple sites within the transmembranous
CTFb generating C-terminally heterogeneous Ab pep-
tides ranging between 38 to 43 amino-acid residues in
length that are secreted [6]. In addition to BACE-1 and
g-secretase, APP can be cleaved by a-secretase within the
Ab domain between Lys16 and Leu17, releasing APPsa
and generating CTFa or C83 which is further cleaved by
g-secretase to generate an N-terminally truncated Ab
termed p3. Genetic ablation of BACE-1 completely
abolishes Ab production, establishing BACE-1 as the
major neuronal enzyme responsible for initiating the
amyloidogenic processing of APP [7].
Given that BACE-1 is the initiating enzyme in Ab
generation, it is considered a prime target for lowering
Ab levels in the treatment and/or prevention of AD.
BACE-1 expression is tightly regulated at both the tran-
scriptional and translational level [8]. The BACE-1 gene
spans approximately 30 kilobases on human chromo-
some 11q23.2 and includes 9 exons. The BACE-1 gene
promoter lacks the typical CAAT and TATA boxes but
contains a variety of transcription factor binding sites,
including those for Sp1, GATA-1, AP1, CREB, HSF-1,
STAT1, and NFB, among others. It is likely that these
sites influence transcriptional activity of the BACE-1
promoter. Interestingly, both the expression and activity
of BACE-1 appear to be elevated in the cerebrospinal
fluid and brains of AD patients [9,10] suggesting that
BACE-1 expression is altered in AD and that therapeu-
tic approaches aimed at regulating BACE-1 expression
may be successful.
Neurons are believed to be the major source of Ab
and BACE-1. However, evidence is mounting that glia,
and astrocytes in particular may produce significant
levels of BACE-1 and Ab, especially during inflamma-
tion. Glia out-number neurons by a factor of 10, so
even a slight increase in glial BACE-1 expression might
contribute substantially to cerebral Ab and exacerbate
AD pathology. NFB is increased in AD and particularly
in astrocytes, and it has been suggested that Ab itself
can trigger BACE-1 expression in glial cells via NFB
activation [11-15]. BACE-1 expression has been shown
to be particularly elevated both in neurons and astro-
cytes around Ab deposits in AD brains [16,17,9]. Thus,
pathophysiological conditions leading to the activation
of astrocytes may increase BACE-1 expression resulting
in increased Ab production which could exacerbate AD
pathogenesis. Small increases in BACE-1 expression
have been shown to result in sharply increased Ab pro-
duction [18]. Altogether these data suggest that lowering
BACE-1 expression levels may have therapeutical poten-
tial for AD. We have therefore explored in vitro the
effects of various known NFB inhibitors as a way to
reduce BACE-1 expression and shown that NFB inhibi-
tors reduce Ab production by targeting the b-cleavage
of APP [19]. In the present study, we investigated acute
and chronic effects of celastrol, a potent natural triter-
pene NFB inhibitor extracted from the roots of the
Chinese “Thunder of God vine” (Tripterygenium wilfor-
dii) on Ab production and Alzheimer-like pathology in
a transgenic mouse model of AD. Root extracts of the
“Thunder of God vine” have been used as an anti-
inflammatory remedy for centuries in China. Celastrol
was selected over other known NFB inhibitors for its
ability to cross the blood brain barrier and offer neuro-
protection in animal models of Parkinson’s disease and
Huntington’s disease [20]. Previous work has revealed
that celastrol can prevent neurodegeneration and extend
the life span of a transgenic mouse model of amyo-
trophic lateral sclerosis [21]. Celastrol displays potent
anti-inflammatory activities in vivo and has been shown,
for example, to be beneficial against allergy-induced
asthma [22] as well as rheumatoid arthritis [23] and to
inhibit tumor cell invasion through suppression of
NFB signaling [24].
Methods
Cell culture and western-blotting experiments
NFB activation was quantified using a stable NFB
luciferase reporter cell line of HEK293 cells with chro-
mosomal integration of a luciferase reporter construct
regulated by 6 copies of the NFB response element
(Panomics, CA, USA). Cells were grown in DMEM con-
taining 10% serum, 1% penicillin/streptomycin/fungi-
zone and 100 μg/ml of hygromycin B. Confluent cells
were treated with 20 pg/ml of TNFa (Sigma, MO, USA)
to induce NFB activation and with a dose range of
celastrol for 3 hours. Celastrol was purchased by Gaia
Chemical Corporation (CT, USA). Luciferase activity
was detected with the Luc-Screen Extended-Glow from
Applied Biosystem (CA, USA) and a Synergy HT Biotek
chemoluminescent reader (VT, USA). The medium sur-
rounding the cells was collected and used to assess cyto-
toxicity using a Lactate Dehydrogenase (LDH) assay
(Roche Diagnostics, Germany) according to the
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manufacturer’s protocol. Similar experiments were also
conducted with 100 ng/ml of phorbol 12-myristate 13
acetate (PMA) purchased from Sigma (MO, USA)
instead of TNFa to induce NFB activation (data not
shown). HEK293 cells were used to assess the effect of
celastrol on the activation of canonical members of the
NFkB signaling pathway following PMA stimulation and
on BACE-1 expression levels. Briefly, HEK293 cells were
treated 100 ng/ml of PMA or a combination of PMA
with celastrol (5 mM) for 15 minutes. Celastrol effects
on RAF-1, MEK1/2, p44/42 MAPK and IKBa phosphor-
ylation were monitored by western-blots as detailed
below.
7 W CHO cells overexpressing wild-type human APP
[25] were grown in DMEM (ATCC, VA, USA) contain-
ing 10% fetal bovine serum (Invitrogen, CA, USA), 1%
penicillin/streptomycin/fungizone (Cambrex, ME, USA)
and 0.3% Geneticin (Invitrogen, CA, USA) and used to
determine the impact of celastrol on APP processing
and Ab production. Confluent cells were treated for 24
hours with different doses of celastrol.
Cellular proteins were extracted with 150 μL of ice-
cold M-PER Reagent (Pierce Biotechnology, Rockford,
IL, USA) containing 1 mM phenylmethanesulfonyl
fluoride, 1× of protease cocktail inhibitor (Roche, Inc.,
USA) and 1 mM sodium orthovanadate. Samples were
sonicated, denatured by boiling in Laemmli buffer (Bio-
Rad, Hercules, CA, USA) and resolved onto 4-20% gra-
dient polyacrylamide gels (Bio-Rad, Hercules, CA, USA).
After electrotransfering onto polyvinylidene difluoride
membranes, western-blots were immunoprobed with an
anti-APP C-terminal (751-770) antibody (EMD Bios-
ciences Inc., San Diego, CA, USA), with an anti-actin
antibody (Chemicon, Temecula, CA, USA) used as a
reference antibody to quantify the amount of proteins
electrotransferred, with a BACE-1 antibody (Invitrogen,
CA, USA), with a phospho-IKBa (ser32) antibody, with
a phospho-NFB p65 (ser 536) antibody, with a phos-
pho-Raf-1 (Ser338) antibody, with a phospho-MEK1/2
and a phospho-p44/42 MAPK antibody using dilutions
recommended by the manufacturers. All phospho-speci-
fic antibodies were purchased from Cell Signaling Tech-
nology Inc (MA, USA). Additionally, sAPPa was
detected by Western-blot in the culture medium sur-
rounding 7 W CHO cells using the antibody 6E10 (Sig-
net Laboratories Inc., MA, USA) which recognizes the
amino-acids 1-17 of Ab and sAPPb was detected in the
culture medium using an anti-human sAPPb antibody
(Immuno-Biological Laboratories Co. Ltd., Gunma,
Japan). APP CTF/actin, sAPPb/sAPPa signals, phospho-
IKBa/actin, phospho-NFB p65/actin, phpspho-RAF-1/
actin, phospho-MEK/actin, phospho-p44/42 MAPK/
actin, BACE-1/actin signal intensity ratios were
quantified by chemiluminescence imaging with the
ChemiDocTM XRS (Bio-Rad, Hercules, CA, USA). Ab
1-40 and Ab 1-42 were quantified in the culture media
of 7 W CHO cells using commercially available
ELISAs following the manufacturer’s recommendations
(Invitrogen, CA, USA).
Short hairpin RNAs (shRNAs) were used to stably
knock-down the cdc37 gene in HEK293 cells overex-
pressing APPsw cells. Three different cdc37 shRNAs
and a scrambled control shRNA (control cells) were
used for transfection. Cdc37 shRNAs cloned into the
pRs vector were purchased from Origene (Rockville,
MD, USA). Approximately one million HEK/APPsw
cells detached with TripLE (Invitrogen, IL, USA) were
mixed together with 10 μg of shRNA vectors in Bio-Rad
(Hercules, CA, USA) gene pulser cuvettes and electro-
porated using a square wave protocol (110 V, one 25 ms
pulse length using a Bio-Rad gene pulser). Forty-eight
hours after, the culture media were replaced by selective
media containing 6 μg/ml of puromycin for stable selec-
tion of transfected cells. Single colonies resistant to pur-
omycin were isolated. Western-blots were run with cell
lysates from these clones to confirm silencing of the
cdc37 gene using a 1:1000 dilution of an anti-cdc37
(V367) antibody (Cell Signaling Technology Inc, MA,
USA). BACE-1 expression and APP-CTF levels were
monitored in cdc37 knock-down HEK293 APPsw cells
and HEK293 APPsw cells transfected with a scrambled
control shRNA vector as described above.
In order to inhibit HSP90, HEK293 APPsw overex-
pressing cells were treated for 24 hours with 10 and 20
μM of gedunin (Tocris, MI, USA), a known HSP90 inhi-
bitor which has been shown to inhibit HSP90 with an
IC50 ranging from 3 μM to 8 μM in function of the cell
type used [26]. Following 24 hours treatment with gedu-
nin, cellular lysates were prepared and assayed for
BACE-1 expression and APP-CTF levels by western
blotting as described above.
The effect of celastrol on the disruption of the cdc37-
HSP90 complex was tested in HEK293 cells overexpres-
sing APPsw. Briefly, HEK293 APPsw cells were treated
with PMA 100 ng/ml and celastrol 5 μM for 3 hours.
Cellular lysates were prepared as described above and
immunoprecipited overnight at 4°C with a 1:100 dilution
of an HSP90 antibody (Cell Signaling Technology Inc,
MA, USA). Protein A sepharose (GE Healthcare, NJ,
USA) was used to pull down the immunoprecipitated
complex which was denatured and analyzed by wester-
nblotting for the presence of cdc37.
Animals and treatments
All the experimentations involving mice were approved
by the Institutional Animal Care and Use Committee of
the Roskamp Institute. Transgenic mice overexpressing
the human APP695sw mutation and the presenilin-1
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mutation M146L (Tg PS1/APPsw) resulting in over
production of human APP and Ab [27] were used to
assess the effect of celastrol on brain Ab levels. These
transgenic mice typically start to develop Ab deposits by
4 month of age and display a significant amount of Ab
deposits by 6 months [27,28]. An acute treatment
regimen was first tested by injecting intraperitoneally
35 week-old Tg PS1/APPsw (post plaque formation)
with 1 mg/Kg body weight of celastrol (n = 7) or with
100 μL of the vehicle (50% DMSO in PBS, n = 7) daily
for 4 days. One hour after the last injection, brains of
the animals were collected, snap frozen in liquid nitro-
gen and stored at -80°C.
Custom made biodegradable pellets ensuring a contin-
uous release of celastrol at 2.5 mg/Kg of body weight/
day and placebo pellets were obtained from Innovative
Research of America (FL, USA). Pellets were implanted
subcutaneously in 5 month-old Tg PS1/APPsw mice
(placebo n = 7; celastrol n = 7) when Ab deposits are
forming. After one month (32 days) of treatment, one
brain hemisphere for each mouse was snap frozen in
liquid nitrogen and stored at -80°C whereas the other
hemisphere was fixed in 4% paraformaldehyde for 48
hours at 4°C prior to embedding in paraffin using a Tis-
sue-Tek automated embedding system (Sakura, USA).
Brain Ab quantifications
Mice brains (not including the cerebellum) were homo-
genized by sonication in ice cold MPER reagent contain-
ing 1 mM PMSF, 100 mM sodium orthovanadate and
1× cocktail of protease inhibitors (Pierce protein
research product, IL, USA). Brain homogenates were
centrifuged at 4°C for 30 min at 15000 rpm. The super-
natant containing soluble Ab (GS) was collected and
treated with 5 M guanidine isothiocyanate for 1 hour at
room temperature. The pellet containing insoluble Ab
(GI) was dissolved and denatured in 5 M guanidine iso-
thiocyanate. Protein concentrations were estimated in
both fractions by the BCA method (Pierce, IL). For the
mice that received an acute treatment with celastrol, Ab
1-40 and Ab 1-42 were quantified by ELISAs according
to the manufacturer’s recommendations (Invitrogen,
CA, USA). For the mice that received the chronic celas-
trol treatment, Ab 1-38, Ab 1-40 and Ab 1-42 were
quantified by electrochemoluminescence in GI and GS
fractions using multiplex Ab assays according to the
manufacturer’s recommendations (Meso Scale Discov-
ery, MD, USA). Ab concentrations were calculated in
pg/mg of protein and expressed as a % of Ab obtained
in the vehicle/placebo treated animals.
Immunohistochemistry
Paraffin embedded brains were sagitally cut into 5 μm-
thick sections with a microtome (2030 Biocut, Reichert/
Leica, Germany). Sections were mounted on slides and
air-dried. Prior to staining, sections were deparaffinized
in xylene (2 × 5 min) and hydrated in graded ethanol
(2 × 5 min in 100%, 5 min in 85%, 5 min 70%) to water.
Endogeneous peroxidase activity was quenched with a
20-min-H2O2 treatment (0.3% in water) and after being
rinsed, sections were incubated with blocking buffer
(Protein Block Serum-free, DakoCytomation) for 20
min. The monoclonal antibody 4G8 was used to stain
Ab deposits at a 1:750-dilution and purchased from
Signet Laboratories (MA, USA). CD45 was immunode-
tected using a 1:50-dilution of a rat monoclonal anti-
body (clone IBL-3/16) from Serotec (NC, USA) and
used as a microglial marker as previously described [29].
The diluted antibodies were applied onto the sections
overnight at 4°C and were detected using the Vectastain
ABC (avidin-biotin-peroxidase complex) Elite kit (Vector
Laboratories, CA). The labeling was revealed by incubat-
ing sections in 0.05 M Tris-HCl buffer (pH 7.6) contain-
ing 3,3’-diaminobenzidine (Sigma, MO) and H2O2. For
each brain, 4 to 5 stained sections were used to perform
the quantification of 4G8 burden and 3 sections were
used for the quantification of CD45 burden. The stained
area within particular regions (hippocampus, cortex)
was quantified using Image-Pro Plus software (Media
Cybernetics, MD). An average value was calculated for
each brain area from individual mice and expressed as a
percentage of the total brain area examined.
Statistical analyses
For statistical analyses, ANOVA, post-hoc comparisons
and t-tests were performed where appropriate using
SPSS for Windows release 12.0.1.
Results
In vitro effects of celastrol
Celastrol (3-Hydroxy-24-nor-2-oxo-1(10),3,5,7-friedelate-
traen-29-oic acid) is a natural triterpene lactone epoxide
compound (Figure 1A) extracted from the root bark of
the Chinese medicine “Thunder of God Vine” which has
been used for hundreds of years as a natural remedy for
inflammatory conditions. Celastrol appears to potently
inhibit NFB activation induced by TNFa as monitored
by measuring luciferase activity in a stable NFB repor-
ter HEK293 cell line with a half maximal inhibitory con-
centration (IC50) below 1 μM (Figure 1B) and no
cytotoxicity was observed for doses of celastrol up to 5
μM (Figure 1C). Similar data were observed with celas-
trol when phorbol ester (PMA) was used in place of
TNFa to induce NFB signaling (data not shown). We
investigated the possible effect of celastrol on some
members of the canonical NFB pathway following
15 minutes of stimulation with PMA. As expected, we
observed that PMA rapidly stimulated the
Paris et al. Journal of Neuroinflammation 2010, 7:17
http://www.jneuroinflammation.com/content/7/1/17
Page 4 of 15
phosphorylation of RAF1, MEK1/2, p44/42 MAPK and
IKBa (Figure 2). Interestingly, celastrol did not prevent
PMA induced phosphorylation of RAF1, MEK1/2 and
p44/42 MAPK but inhibited PMA induced IKBa phos-
phorylation suggesting that celastrol inhibits the activity
of the IKK (IKappa B Kinase) signaling complex. The
IKK signaling complex is also comprised of the catalytic
components IKKa, IKKb and of the regulatory subunit
NEMO (NFB essential modifying factor) which inte-
grates upstream signals and leads to the phosphorylation
of IKBa and NFB. Subsequently, phosphorylated IKBa
is ubiquitinated and rapidly degraded allowing the loca-
lization signal for NFB nuclear translocation to be
exposed.
We used 7 W CHO cells overexpressing wild-type
human APP [25] to assess the effect of celastrol on Ab
production and APP processing. Following a 24 hours
treatment, celastrol inhibited Ab1-42 and Ab1-40 produc-
tion with an IC50 of approximately 900 nM (Figure 3A) in
7 W CHO cells overexpressing APP. Analysis of metabo-
lites of the APP pathway reveals that celastrol impairs the
cleavage of APP at the b-secretase cleavage site leading to
a decreased sAPPb and concomitant suppression of the
APP-CTFb (C99) fragment (Figure 3B). No significant
effect of celastrol was observed on APPsa secretion indi-
cating that celastrol does not affect the a-secretase clea-
vage of APP despite a reduction in APP-CTFa (C83) at 5
μM, therefore suggesting that celastrol may affect the sta-
bility or turn-over of C83 (Figure 3B). We did not find
that celastrol directly affects BACE-1 activity in a cell free
assay at doses inhibiting Ab production in whole cells
(data not shown). A dose dependent inhibition of IKBa
and NFB p65 phosphorylation was observed with celas-
trol confirming that celastrol inhibited basal NFB activity
in 7 W CHO cells overexpressing APP at doses affecting
APP processing (Figure 3). We investigated the effect of
celastrol and NFB stimulation with PMA on BACE-1
expression in HEK293 cells overexpressing APPsw (Figure
4). Celastrol inhibited basal BACE-1 expression and
opposed the stimulation of BACE-1 expression induced by
PMA. In parallel with the reduction of BACE-1 expression
induced by celastrol, a reduction in APP-CTFb was
observed. Moreover, an increased in APP-CTFb and
BACE-1 levels was observed when NFB signaling was sti-
mulated by PMA (Figure 4) suggesting that celastrol
affects APP processing by regulating BACE-1 expression
via an NFB dependent mechanism. Similarly, using a
neuronal like cell line (SHSY), we observed that celastrol
can reduce BACE-1 expression and oppose PMA induced
BACE-1 expression (data not shown).
Since the formation of a transient complex between
cdc37 and HSP90 may be required to allow IKK activa-
tion [30] and celastrol may interfere with HSP90 or
Figure 1 A) Chemical structure of celastrol, an active
ingredient of the “Thunder of God” medication which has
been used as an anti-inflammatory remedy for centuries in
China. B) Dose dependent effect of celastrol on NFB activation
induced by TNFa in HEK293 cells stably expressing an NFB
luciferase reporter construct. Cells were co-treated with 20 pg/ml of
TNFa and with a dose range of celastrol for 3 hours before
measuring NFB luciferase activity. ANOVA reveals a statistically
significant main effect of celastrol dose on NFB activation (P <
0.002). Post-hoc analysis show significant differences between NFB
activity in TNFa treated cells and cells co-treated with TNFa and
celastrol for celastrol doses greater or equal to 10 nM (P < 0.005). C)
The histogram represents the amounts of LDH released detected in
the culture medium of HEK293 cells treated with a dose range of
celastrol and with the MPER lysis buffer as a positive control (lysis
buffer) to induce complete cellular lysis. ANOVA reveals no
significant main effect of celastrol dose (P = 0.420) and a significant
effect of the lysis buffer (P < 0.001) on LDH released.
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Figure 2 Effect of celastrol on phorbol ester (PMA) induced phosphorylation of key members of the NFB signaling pathway. HEK293
cells overexpressing APPsw were treated for 15 minutes with PMA in the presence of 0 μM and 5 μM of celastrol. A) Western blots reveal that
celastrol did not inhibit Raf-1 phosphorylation, MEK1/2 phosphorylation or p44/42 MAPK phosphorylation induced by PMA but prevented IKBa
phosphorylation induced by PMA suggesting that celastrol is inhibiting IKK activity. B) Histogram representing the quantification of Raf-1
phosphorylation/actin, MEK1/2 phosphorylation/actin, phospho p44/42 MAPK/actin and IKBa phosphorylation/actin chemoluminescent signal.
ANOVA shows a significant main effect of PMA on the phosphorylation of these different proteins (P < 0.05). Post-hoc comparisons reveal
significant increase in phosphorylation after PMA treatment for Raf-1 (P < 0.04), MEK1/2 (P < 0.01), p44/42 MAPK (P < 0.001) and IKBa (P < 0.001)
compared to the control conditions. Celastrol does not appear to prevent PMA induced Raf-1 phosphorylation (P = 0.619) but leads to a
significant stimulation of MEK1/2 and p44/42 MAPK compared to PMA treatment alone (P < 0.02) and significantly inhibited IKBa
phosphorylation compared to PMA treatment alone (P < 0.001).
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Figure 3 A) Effect of celastrol on Ab production in 7 W CHO cells overexpressing wild-type human APP. Human Ab was measured by
ELISAs in the culture media surrounding the cells following 24 hours of treatment with different doses of celastrol. Dose response curves for both
Ab1-40 and Ab1-42 were established revealing an IC50 of approximately 900 nM for celastrol. ANOVA reveals a significant main effect of celastrol on
Ab 1-40 (P < 0.001) and Ab 1-42 production (P < 0.015). Post-hoc comparisons show statistically significant effects of celastrol at 1000 nM, 25000
nM and 5000 nM for both Ab 1-40 and Ab 1-42 (P < 0.001). B) Effect of celastrol on APP processing and NFB in CHO cells overexpressing wild-
type human APP. Celastrol dose dependently inhibited APPsb secretion, APP-CTFb level as well as NFB p65 and IKBa phosphorylation. C)
Histogram representing the quantification of APPsb/APPsa, APP-CTFb/actin as well as phospho-NFB p65/actin and phospho-IKBa/actin
chemoluminescent signals. ANOVA reveals a significant main effect of celastrol on APPsb secretion, APP-CTFb level, phospho-NFB p65 and
phospho-IKBa levels (P < 0.001). Post-hoc comparisons show a statistical significance for celastrol at 2 and 5 μM for all the parameters studied
(P < 0.05) showing that celastrol dose dependently inhibits the b-cleavage of APP while suppressing NFB activity. (* P < 0.05; ** P < 0.001).
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cdc37 [31,32], we explored the effect of celastrol on the
formation of this complex in HEK293 cells overexpres-
sing APPsw. Data show that at a dose (5 μM) that fully
inhibits NFB activation and Ab production, only a slight
reduction of cdc37 was observed in the immunoprecipi-
tated HSP90 complex (Figure 5A and 5B). No effect of
the NFB stimulator PMA was observed on the stability
of this complex. We next inhibited HSP90 in HEK293
APPsw cells using gedunin, a known HSP90 inhibitor
[26] which induces the degradation of HSP90-dependent
client proteins similarly to other HSP90 inhibitors. Gedu-
nin did not appear to affect BACE-1 expression or APP
processing (Figure 5C and 5D). Moreover, we stably
knock-down cdc37 expression in HEK293 APPsw cells
using a shRNA approach and observed that cdc37 inhibi-
tion did not impact BACE-1 expression (Figure 5E and
5F) and APP processing (data not shown).
Acute effect of celastrol on Ab production in a transgenic
mouse model of AD
We next investigated the effect of celastrol on brain Ab
levels using an acute dosage paradigm in 6-month old
Tg PS1/APPsw mice. Tg PS1/APPsw mice were injected
intraperitoneally, daily for 4 days, with 1 mg/Kg of body
weight of celastrol or 100 μL of the vehicle only. One
hour after the last injection, mice were humanely eutha-
natized and their brains collected. We assessed the
b-amyloid lowering properties of celastrol by measuring
the pools of soluble and insoluble Ab species in celas-
trol and placebo treated mice. Following 4 days of treat-
ment with 1 mg/Kg/day of celastrol, we observed a
reduction in brain soluble Ab 1-40 and Ab 1-42 by
approximately 40% whereas insoluble Ab was reduced
by approximately 50% compared to placebo treated
animals (Figure 6).
Figure 4 A) Representative western-blot depicting the effect of celastrol on BACE-1 expression in HEK293 cells overexpressing APPsw.
Celastrol inhibited basal BACE-1 expression as well as the stimulation of BACE-1 expression induced by a 24 hours treatment with PMA. APP-
CTFb level is reduced when BACE-1 expression is inhibited by celastrol and APP-CTFb level is increased when BACE-1 expression is stimulated by
PMA. B) Histogram representing the quantification of BACE-1 expression in response to celastrol and PMA treatments. ANOVA reveals a
significant main effect of PMA (P < 0.002) and of celastrol (P < 0.001) on BACE-1 expression. Post-hoc comparisons shows that PMA significantly
stimulates BACE-1 level (P < 0.002) whereas celastrol significantly reduces BACE-1 expression (P < 0.001) compared to control condition and
opposes BACE-1 stimulation induced by PMA (P < 0.001). (** P < 0.002).
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Figure 5 Effect of celastrol and PMA on the formation of the HSP90-cdc37 complex in HEK293 APPsw cells. A) Western-blot depicting
the amount of cdc37 recovered in the HSP90 immunoprecipitate following treatment with celastrol and PMA. B) Histogram representing the
quantification of cdc37 in the HSP90 immunoprecipitate. No significant effect of PMA was observed but a significant effect of celastrol was
detected (P < 0.005) showing a slight reduction in the amount of cdc37 present in the HSP90 immunoprecipitates. C) Western-blots showing
the effects of the HSP90 inhibitor gedunin on BACE-1 expression and APP processing in HEK293 APPsw cells. D) Histogram representing the
quantification of BACE-1/Actin chemoluminescent signal showing that the gedunin treatment does not affect BACE-1 expression in HEK293
APPsw cells (ANOVA reveals no significant main effect of gedunin on BACE-1 level (P = 0.572)). E) Representative western-blot showing the level
of cdc37 and BACE-1 expression in HEK293 APPsw cells that were knock-down for cdc37 using a shRNA approach for 3 different clones. 1) non
silencing scrambled shRNA; 2) cdc37 shRNA clone 51G9; 3) cdc37 shRNA clone 97H1; 4) cdc37 shRNA clone 95C4. F) Histogram representing the
quantification of cdc37 and BACE-1 expression for 9 different clones of HEK293 APPsw cells stably transfected with a silencing cdc37 shRNA
vector (cdc37 shRNA) and 4 different clones of HEK293 APPsw stably transfected with a non silencing scrambled shRNA vector (control shRNA).
Statistically significant inhibition of cdc37 expression (P < 0.001) and no effect on BACE-1 expression (P = 0.947) was observed in HEK293 APPsw
cells knock-down for cdc37.
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Chronic effect of celastrol on Alzheimer-like pathology in
a transgenic mouse model of AD
To evaluate whether celastrol could affect Alzheimer-
like pathology in Tg PS1/APPsw, we investigated the
effects of a longer treatment with celastrol. We used a
matrix-driven delivery pellet system implanted subcuta-
neously that was designed to ensure a continuous deliv-
ery of celastrol and avoid subjecting the animals to
repeated injections and excessive handling. Tg PS1/
APPsw mice were treated for one month with this pellet
delivery system at a dosage of 2.5 mg of celastrol/Kg of
body weight/Day. Analysis of brain Ab levels by ELISAs
revealed that celastrol reduced brain soluble Ab 1-38,
Ab 1-40 and Ab 1-42 by approximately 50% and the
levels of insoluble Ab 1-38, Ab 1-40 and Ab 1-42 by
approximately 60% (Figure 7). To determine whether
celastrol treatment affected b-amyloid plaque pathology,
brain sections from Tg PS1/APPSw mice implanted
with a placebo pellet and Tg PS1/APPSw mice
implanted with a celastrol pellet were immunostained
with the antibody 4G8 recognizing Ab. A significant
reduction in plaque burden (approximately 50%) in both
the hippocampus and the cortex of celastrol treated ani-
mals compared to animals receiving the placebo was
observed (Figure 8). We also estimated the impact of
celastrol on microglial activation by measuring the per-
centage of CD45 immunostained area [29] on brain
sections in placebo and celastrol treated animals. An
approximate 50% reduction in microgliosis was observed
in the cortex of celastrol treated animals compared to
placebo treated animals (Figure 9).
Discussion
NFB has been shown to regulate BACE-1 expression
level [11,17,13-15], the rate limiting enzyme responsible
for the production of Ab. For this reason, we investi-
gated whether NFB inhibition could lead to an inhibi-
tion of Ab accumulation in a transgenic mouse model
of AD. In this study, we selected the natural product
celastrol over other known NFB inhibitors because it is
a potent NFB inhibitor that has been shown to exert
anti-inflammatory effects in vivo [33,34] and neuropro-
tective effects in animal models of Parkinson’s disease
and Hungtington’s disease [20]. We first characterized
the in vitro activity of celastrol towards Ab production
using a CHO cell line overexpressing Ab. Celastrol dose
dependently inhibited Ab1-40 and Ab1-42 with an IC50
comparable to its IC50 for inhibiting NFB activation in
response to TNFa (around 900 nM). Celastrol dose
dependently reduced the production of APP-CTFb and
APPsb confirming that celastrol impacted the b-cleavage
of APP. Moreover, celastrol appeared to reduce BACE-1
expression and to oppose BACE-1 upregulation induced
by NFB stimulation.
Figure 6 Acute effects of celastrol on brain Ab levels in 35 week-old Tg PS1/APPSw. Mice were treated for 4 days with an intraperitoneal
injection of celastrol (1 mg/Kg of body weight) or the vehicle only (placebo). Multivariate analysis reveals a significant main effect of celastrol on
brain soluble and insoluble Ab levels (P < 0.05). Statistically significant differences were observed for soluble Ab 1-42 values (P < 0.03) between
vehicle and celastrol treated mice and for insoluble Ab 1-40 (P < 0.001) and Ab 1-42 values (P < 0.001) between vehicle and celastrol treated
mice. (* P < 0.05; ** P < 0.001).
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We then investigated the impact of celastrol on Ab
production in vivo using a transgenic mouse model of
AD. Following an acute treatment with celastrol in Tg
PS1/APPsw, we observed a reduction in brain soluble
and insoluble Ab species. We used a biodegradable pel-
let delivery system implanted subcutaneously to assess
the Ab lowering effects of a chronic treatment with
celastrol. After 1 month of treatment, pathological
evaluation of the brains of celastrol treated Tg PS1/
APPsw mice showed a 50% reduction in Ab plaque bur-
den in the hippocampus and cortex compared to pla-
cebo treated animals. Additionally, evaluation of
activated microglia following CD45 immunostaining
revealed that microgliosis was significantly reduced in
celastrol treated animals compared to placebo treated
mice paralleling the reduction of Ab burden observed.
Figure 7 Chronic effects of celastrol on brain Ab levels. Five month-old Tg PS1/APPsw mice were implanted subcutaneously with
biodegradable placebo pellets and celastrol pellets ensuring a constant release of celastrol at a rate of 2.5 mg/Kg of body weight/day. After 32
days of treatment, brain Ab levels were analyzed by electrochemoluminescence. A) Histogram representing the level of soluble Ab 1-38, Ab 1-40
and Ab 1-42 quantified in the brain of placebo and celastrol treated Tg PS1/APPsw mice. B) Histogram representing the level of insoluble Ab
1-38, Ab 1-40 and Ab 1-42 quantified in the brain of placebo and celastrol treated Tg PS1/APPsw mice. Multivariate analysis reveals a statistical
significant differences between celastrol and placebo treated mice for the levels of brain soluble Ab 1-38 (P < 0.005), Ab 1-40 (P < 0.03), Ab 1-42
(P < 0.007) and brain insoluble Ab 1-38 (P < 0.004), Ab 1-40 (P < 0.03), Ab 1-42 (P < 0.02). (* P < 0.05); ** P < 0.01).
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We further characterized the b-amyloid lowering prop-
erties of celastrol by measuring the pools of soluble and
insoluble Ab species in celastrol and placebo treated
mice. Data showed that this chronic treatment with
celastrol in Tg PS1/APPsw mice reduced brain levels of
soluble Ab 1-38, Ab 1-40 and Ab 1-42 by approximately
50% and the levels of insoluble Ab 1-38, Ab 1-40 and
Ab 1-42 by approximately 60%.
The exact molecular mechanism of action of celastrol
remains unclear. Celastrol has been suggested to be an
ERK inhibitor and to inhibit of p44/42 MAPK phos-
phorylation [35], however our data show that celastrol
inhibits NFB activation without preventing the
phosphorylation of MEK1/2 and its downstream target
p44/42 MAPK when NFB is stimulated with PMA,
suggesting that celastrol is acting downstream of MAPK.
Indeed, celastrol appears to oppose both IKBa and
NFB p65 phosphorylation which suggest that celastrol
is inhibiting the IKK complex in agreement with pre-
vious studies showing that celastrol inhibits IKK activity
[36]. It has been recently suggested that celastrol inter-
acts with HSP90 and disrupts the formation of the
cdc37-HSP90 complex [31]. However, NMR analyses of
celastrol binding to cdc37 and HSP90 have suggested
that celastrol directly interacts with ccd37 and not
HSP90 [32]. Interestingly, the formation of a transient
Figure 8 Chronic effects of celastrol on Ab plaque burden in Tg PS1/APPsw mice. A) Representative photomicrographs (200×
magnification) showing the extent of Ab plaque burden detected by 4G8 immunostaining in the cortex (right panel) and hippocampus (left
panel) of Tg PS1/APPsw mice (6 month-old) treated with biodegradable pellets of placebo or celastrol for a period of 32 days. B) Histogram
representing the quantification of Ab burden by image analysis in the cortex and hippocampus of Tg PS1/APPsw mice treated with placebo and
celastrol pellets. Multivariate analysis reveals a statistically significant effect of celastrol treatment on Ab plaque burden for the cortex (P < 0.002)
and hippocampus (P < 0.004). (**P < 0.005).
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complex between cdc37 and HSP90 may be required to
allow IKK activation [30] suggesting that celastrol may
inhibit NFB activation by preventing the formation of
this complex. However, the disruption of the cdc37-
HSP90 complex by celastrol requires 10 μM of celastrol
[31] and at 5 μM (dose that fully inhibits Ab production
and NFB activity in vitro), we only observed a modest
reduction (20%) in the amount of cdc37 co-immunopre-
cipited with HSP90 suggesting that the effect of celastrol
on Ab production is unlikely to be mediated via a dis-
ruption of this complex. This is further substantiated by
our observation that pharmacological inhibition of
HSP90 does not significantly affect APP processing and
BACE-1 expression, ruling out the possibility that the
Ab lowering properties of celastrol are mediated via
HSP90 dependent events. Moreover, inhibition of cdc37
expression does not appear to affect APP processing
and BACE-1 expression excluding cdc37 as a molecular
Figure 9 Chronic effects of celastrol on microgliosis in Tg PS1/APPsw mice. A) Representative photomicrographs (taken with a 20× and
60× objective providing a respective magnification of 200× and 600× respectively) depicting the presence of CD45 reactive microglia around
Ab deposits in Tg PS1/APPsw treated with a placebo and celastrol. B) Histogram representing the burden of activated microglia (CD45 positive)
in the cortex of Tg PS1/APPsw mice treated with placebo and celastrol pellets. Statistically significant difference in microgliosis burden (P < 0.03)
was observed between placebo and celastrol treated mice. (* P < 0.05).
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target responsible for the Ab lowering properties of
celastrol. Celastrol has also been shown to inhibit lipido-
peroxydation in vitro with an IC50 of 7 μM [37], which
is 7-fold higher than it’s IC50 for inhibiting Ab produc-
tion; it is therefore unlikely that the antioxidant proper-
ties of celastrol play a major role in the Ab lowering
activity of this compound. Overall, our in vitro data sug-
gest that celastrol inhibits Ab production by regulating
BACE-1 expression level most likely via an NFB
dependent mechanism.
At doses similar to the doses of celastrol that we
tested in vivo, celastrol has been shown to significantly
inhibit NFB activity in the brain, to reduce TNFa pro-
duction and the expression of the CD40 ligand in astro-
cytes [20]. It remains possible that the in vivo Ab
lowering properties of celastrol may be the result of
multiple mechanisms in addition to those affecting APP
processing and BACE-1 expression as observed in vitro.
For instance, celastrol may also lower brain Ab levels by
opposing inflammation, cytokines production and CD40
ligand expression, all of which are known to modulate
the accumulation of Ab in the brain [38-40]. So far, we
have tested the effects of celastrol on brain Ab accumu-
lation when Ab deposits are initially forming in a trans-
genic mouse model of AD, which could be regarded as
an early intervention. It remains to be determined
whether celastrol can display therapeutic efficacy when
Ab deposits are already highly abundant. Interestingly,
celastrol has been shown to display neuroprotective
effects in different animal models [20,21] and to
improve memory, learning and psychomotor activity in
rats [34]. Chronic effects of celastrol on memory impair-
ment and tau pathology remain to be investigated in
transgenic mouse models of AD to determine whether
this compound may offer therapeutic benefits suitable
for the treatment of AD.
Conclusions
Our data suggest that celastrol is a potent Ab lowering
compound that may act in part by decreasing BACE-1
expression levels and Ab production via an NFB
dependant mechanism. More experimentation is
required to determine the exact mechanism of action
responsible for the Ab lowering properties of celastrol.
It remains to be determined whether this compound
can also improve cognition and tau pathology in trans-
genic mouse models of AD and whether this molecule
displays the pharmacokinetic characteristics and toxicity
profile required for a drug candidate.
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